The development of Gardos channel inhibitors will require rigorous preclinical testing and subsequent clinical trials to ensure their safety and efficacy. These trials will help determine the optimal dosage, administration routes, and any potential side effects.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
Benzenemethanol, 2-fluoro-a-(4-fluorophenyl)-a-phenyl-
3-[2-(6-chloropyridazin-3-ylamino)phenylamino]-1H-pyrazol-5(4H)-one
ethyl-5-(2,4-dibenzyloxy-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate
Hexanoic acid, 4-oxo-6-[[(phenylmethoxy)carbonyl]amino]-
N,N'-(6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-2,8-diyldi-2,1-ethanediyl)-bis[N-(2-methoxycarbonylethyl)phenethylamine]
ethyl 2-benzoyl-5-phenyl-1-(4-(phenylethynyl)phenyl)-1H-pyrrole-3-carboxylate
N1-(7-chloroquinolin-4-yl)-N2-{2-[(dimethylamino)methyl]benzyl}ethan-1,2-diamine
